Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small molecules with EGFR-TK inhibitor activity.

Current drug targets - 1 May 2005

Albanell Joan, Gascón Pere

Abstract excerpt

Specific and reversible EGFR tyrosine kinase inhibitors (TKI) such as gefitinib and erlotinib are clinically active in advanced or metastatic NSCLC and both are approved in various countries for the treatment of patients that failed prior chemotherapy. Erlotinib has also prolonged survival in pancreatic cancer patients when added to gemcitabine and regulatory approval in this disease is being sought. Additional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoquinolines
Share to Aniline Compounds
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Intracellular Signaling Peptides and Proteins

Share to Organic Chemicals

Share to Quinazolines

Source

Identifiers

PMID: 15857287
DOI: 10.2174/1389450053765888

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small molecules with EGFR-TK inhibitor activity.PMID 15857287Read ↗

Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.Semantic proximity Read ↗

Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR.Semantic proximity Read ↗

EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidenceSemantic proximity Read ↗

Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles.Semantic proximity Read ↗

Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.Semantic proximity Read ↗

COTI-2, a novel small molecule that is active against multiple human cancer cell linesin vitroandin vivoSemantic proximity Read ↗

Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast CancerSemantic proximity Read ↗

Phase II Studies of Modern Drugs Directed Against New Targets: If You Are Fazed, Too, Then Resist RECISTSemantic proximity Read ↗

Discovery of selective irreversible inhibitors for EGFR-T790M.Semantic proximity Read ↗

The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung CancerSemantic proximity Read ↗

Erlotinib.Semantic proximity Read ↗

[New era in cancer therapy. Gefitinib: small molecule--strong action].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.